TLR9 and cancer: This synthetic, short, single‐stranded oligonucleotide activates Th1 responses via interaction with TLR9, and due to inhibition of Th2 responses by Th1 cytokines, including IFN‐γ and IL‐12; this motif is useful in cancer immunotherapy 63.